ArticleEClinicalMedicine2025
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Next-Generation HIV-1 Therapeutics in Co-Endemic Settings.Biomedicines · 2026Review
- Maturation inhibitors: a lost cause?EClinicalMedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is an unmet need for antiretrovirals with novel mechanisms of action that can provide additional options for people with HIV-1. DOMINO evaluated the efficacy and safety of the maturation inhibitor GSK3640254 (GSK'254) plus two nucleoside reverse transcriptase inhibitors (NRTIs) in adults naive to antiretroviral therapy. Methods: This partially blinded, multicentre phase 2b trial enrolled people with HIV-1 from 54 centres in ten countries (Argentina, Canada, France, Germany, Italy, Portugal, Russian Federation, South Africa, Spain, and the United States). Eligible participants were adults with plasma HIV-1 RNA ≥1000 copies/mL and CD4+ T-cell count ≥250 cells/mm Findings: Screenings occurred between November 18, 2020, and January 31, 2022; 161 participants were randomised (sex assigned at birth: 24% female; 76% male). At Week 24, proportions with HIV-1 RNA <50 copies/mL were 83% (33/40), 91% (39/43), and 76% (32/42) in the GSK'254 100-mg, 150-mg, and 200-mg groups, respectively, vs 92% (33/36) in the DTG group. One participant receiving DTG and eight participants receiving GSK'254 had protocol-defined virologic failure (no resistance detected). All GSK'254 doses were generally well tolerated, with few participants reporting drug-related serious adverse events (GSK'254: 150 mg, 2% [1/43]; 200 mg, 2% [1/42]). Interpretation: GSK'254 plus two NRTIs demonstrated efficacy and safety with no treatment-emergent resistance, consistent with DTG plus two NRTIs, supporting potential further evaluation of maturation inhibitors. Funding: ViiV Healthcare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.